scholarly journals Circulating Tumor Cells In Patients Undergoing Androgen Deprivation Therapy With Versus Without Cryosurgery For Metastatic Prostate Cancer: : A Retrospective Analysis

2021 ◽  
Author(s):  
Mingxiong Sheng ◽  
Shanming Guo ◽  
Chunxiao Liu
Keyword(s):  
Prostate Cancer ◽  
Treatment Response ◽  
Retrospective Analysis ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Cox Regression ◽  
Androgen Deprivation ◽  
Post Treatment

Abstract Background: The study aimed to assess the value of circulating tumor cells (CTCs) as a prognostic and treatment response marker in patients undergoing androgen deprivation therapy (ADT) plus cryosurgery vs. ADT alone for metastatic prostate cancer (mPCA).Methods: This retrospective analysis included 43 patients with mPCA: 23 receiving ADT alone (control) and 20 receiving additional cryosurgery (cryosurgery group).CTCs and progression-free survival(PFS) were compared between the two groups. Cox proportional hazards regression was conducted to identify variables associated with PFS.Results: Median PFS was 35 months (IQR: 33-37) in the cryosurgery group vs. 30 months (IQR: 27-32) in the control (p<0.001). CTCs count was significantly lower in the cryosurgery group at both 3 months (z=2.170, p=0.030) and 12 months (z=2.481; p=0.013). In comparison to the baseline, the number of CTCs at both 3 and 12 months was lower in the cryosurgery group (p=0.004 and p<0.001, respectively), but not in the ADT alone group. In multivariate Cox regression, shorter PFS was associated with baseline PSA ≧100 ng/ml (HR 6.584, 95%CI: 5.309-8.166), biopsy Gleason score≧8 (HR 2.064, 95%CI: 1.608-2.650), clinic T stage＞T2b (HR 5.021, 95%CI: 3.925-6.421), number of bone metastases＞3 (HR 3.421, 95%CI: 2.786-4.202), positive CTCs at 3 months post-treatment (HR 6.833, 95%CI: 5.176-9.022), positive CTCs 1 year post-treatment (HR 6.051, 95%CI: 4.347-8.424). Prostate cryosurgery was associated with longer PFS(HR 0.062, 95%CI: 0.048-.080). Conclusions: CTC was a prognostic and treatment response marker for mPCA. ADT plus cryosurgery could reduce CTCs and prolong PFS vs. ADT alone in mPCA patients with low metastatic volume.

scholarly journals Circulating tumor cells in patients undergoing androgen deprivation therapy with versus without cryosurgery for metastatic prostate cancer: a retrospective analysis

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Mingxiong Sheng ◽  
Shanming Guo ◽  
Chunxiao Liu
Keyword(s):  
Prostate Cancer ◽  
Treatment Response ◽  
Retrospective Analysis ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Cox Regression ◽  
Androgen Deprivation ◽  
Post Treatment

Abstract Background The study aimed to assess the value of circulating tumor cells (CTCs) as a prognostic and treatment response marker in patients undergoing androgen deprivation therapy (ADT) plus cryosurgery vs. ADT alone for metastatic prostate cancer (mPCA). Methods This retrospective analysis included 43 patients with mPCA: 23 receiving ADT alone (control) and 20 receiving additional cryosurgery (cryosurgery group). CTCs and progression-free survival (PFS) were compared between the two groups. Cox proportional hazards regression was conducted to identify variables associated with PFS. Results Median PFS was 35 months (IQR, 33‑37) in the cryosurgery group vs. 30 months (IQR, 27‑32) in the control (p < 0.001). CTCs count was significantly lower in the cryosurgery group at both 3 months (z = 2.170, p = 0.030) and 12 months (z = 2.481; p = 0.013). In comparison to the baseline, the number of CTCs at both 3 and 12 months was lower in the cryosurgery group (p = 0.004 and p < 0.001, respectively), but not in the ADT alone group. In multivariate Cox regression, shorter PFS was associated with baseline PSA ≧100 ng/ml (HR 6.584, 95% CI, 5.309‑8.166), biopsy Gleason score ≧ 8 (HR 2.064, 95% CI, 1.608‑2.650), clinic T stage>T2b (HR 5.021, 95% CI, 3.925‑6.421), number of bone metastases>3 (HR 3.421, 95% CI, 2.786‑4.202), positive CTCs at 3 months post-treatment (HR 6.833, 95% CI, 5.176‑9.022), positive CTCs 1 year post-treatment (HR 6.051, 95% CI, 4.347‑8.424). Prostate cryosurgery was associated with longer PFS (HR 0.062, 95% CI, 0.048‑.080). Conclusions CTC was a prognostic and treatment response marker for mPCA. ADT plus cryosurgery could reduce CTCs and prolong PFS vs. ADT alone in mPCA patients with low metastatic volume.

Neoadjuvant enzalutamide and androgen deprivation therapy for high-risk prostate cancer: Early results from a feasibility trial.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 94-94 ◽  
Author(s):  
David James VanderWeele ◽  
Baris Turkbey ◽  
Fatima Karzai ◽  
Stephanie Harmon ◽  
Adam G. Sowalsky ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Radical Prostatectomy ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Tumor Volume ◽  
Androgen Deprivation ◽  
Post Treatment ◽  
Feasibility Trial ◽  
Localized Disease

94 Background: Intensive androgen-targeted therapy improves survival for patients with androgen naive metastatic prostate cancer. Neoadjuvant androgen deprivation therapy (nADT) with abiraterone for localized disease leads to complete responses (pCR) rates of up to 10%. In this study we tested the efficacy of nADT with enzalutamide for patients with high risk, localized disease and the ability of post-treatment multiparametric MRI (mpMRI) to evaluate response. Methods: A single institution trial (NCT02430480) evaluated nADT and enzalutamide 160 mg daily in patients with high risk non-metastatic prostate cancer. Patients underwent MRI-TRUS-guided fusion biopsy at screening and repeat mpMRI followed by radical prostatectomy (RP) after completing six months of therapy. Results: Twenty patients have completed therapy and undergone radical prostatectomy. Clinical characteristics were typical of those with high risk disease: median PSA 8.96 ng/ml (range 2.07-985.9) and clinical stage by mpMRI cT2 (one patient), cT3 (17 patients), or cT4 (2 patients); 7 patients had enlarged pelvic lymph nodes. Following 6 months of therapy, median pre-RP PSA was < 0.02 ng/ml (range < 0.02 – 0.35). On final pathology, 0 patients were upstaged, 5 (25%) were unchanged, and 15 (75%) were downstaged, including 3 (16%) pCR. Four patients were downstaged from N1 to N0. There was little correlation between post-treatment mpMRI tumor volume and pathologic tumor volume. Two patients had radiographic complete responses, one of whom had extensive residual disease. Conclusions: Six months of nADT with enzalutamide has activity in high risk, localized prostate cancer, with a small number of patients having exceptional responses. Standard analysis of mpMRI does not reliably characterize depth of response. Evaluation of molecular characteristics that predict exceptional response or intrinsic resistance is on-going. Patients are being followed for recurrence. Clinical trial information: NCT02430480.

EFFECT OF ANDROGEN DEPRIVATION THERAPY ON DISSEMINATED TUMOR CELLS IN MEN WITH PROSTATE CANCER

2009 ◽  
Vol 181 (4S) ◽  
pp. 775-775
Author(s):  
Todd M. Morgan ◽  
Theodore D. Koreckij ◽  
Daniel W. Lin ◽  
William J. Ellis ◽  
Ian S. Gallaher ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Cells ◽  
Androgen Deprivation Therapy ◽  
Disseminated Tumor Cells ◽  
Androgen Deprivation

scholarly journals NRG1 Genetic Variant Influences the Efficacy of Androgen-Deprivation Therapy in Men with Prostate Cancer

Biomedicines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 528
Author(s):  
Shu-Pin Huang ◽  
Yei-Tsung Chen ◽  
Lih-Chyang Chen ◽  
Cheng-Hsueh Lee ◽  
Chao-Yuan Huang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Tyrosine Kinases ◽  
Multiple Testing ◽  
Cox Regression ◽  
Progression Free Survival ◽  
Androgen Deprivation ◽  
Nucleotide Polymorphisms ◽  
Multiple Testing Correction ◽  
Cancer Specific Survival

Neuregulins (NRGs) activate receptor tyrosine kinases of the ErbB family, and play essential roles in the proliferation, survival, and differentiation of normal and malignant tissue cells. We hypothesized that genetic variants of NRG signalling pathway genes may influence treatment outcomes in prostate cancer. To test this hypothesis, we performed a comprehensive analysis to evaluate the associations of 459 single-nucleotide polymorphisms in 19 NRG pathway genes with cancer-specific survival (CSS), overall survival (OS), and progression-free survival (PFS) in 630 patients with prostate cancer receiving androgen-deprivation therapy (ADT). After multivariate Cox regression and multiple testing correction, we found that NRG1 rs144160282 C > T is significantly associated with worsening CSS, OS, and PFS during ADT. Further analysis showed that low expression of NRG1 is closely related to prostate cancer, as indicated by a high Gleason score, an advanced stage, and a shorter PFS rate. Meta-analysis of 16 gene expression datasets of 1,081 prostate cancer samples and 294 adjacent normal samples indicate lower NRG1 expression in the former compared with the latter (p < 0.001). These results suggest that NRG1 rs144160282 might be a prognostic predictor of the efficacy of ADT. Further studies are required to confirm the significance of NRG1 as a biomarker and therapeutic target for prostate cancer.

scholarly journals Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer

Cancer ◽  
2018 ◽  
Vol 125 (3) ◽  
pp. 453-462 ◽  
Author(s):  
Hala T. Borno ◽  
Daphne Y. Lichtensztajn ◽  
Scarlett L. Gomez ◽  
Nynikka R. Palmer ◽  
Charles J. Ryan
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Androgen Deprivation
Sign in / Sign up

Export Citation Format

Share Document